China’s most important annual government meetings, known as the “Two Sessions,” kicked off March 4 and biopharma executives that were also delegates to the National People's Congress (NPC) suggested that approval for trials should be stricter to avoid repetitive R&D and called for innovative drugs to get into the state insurance list – and to patients – faster.
HONG KONG – Singapore-based X-Zell Biotech Pte. Ltd. has emerged as the winner of the Medtech Innovator Asia Pacific 2020 Accelerator program, as determined by a live virtual audience vote. Winning the competition, organized by Medtech Innovator and the Asia Pacific Medical Technology Association (APACMed), earned X-Zell a $150,000 non-dilutive grand prize to advance its business goals and mission.
HONG KONG – Los Angeles-based medical device accelerator Medtech Innovator and Asia Pacific Medical Technology Association (APACMed) have picked five finalists to compete for the title of the 2020 Asia Pacific Grand Prize winner, out of more than 170 applicants. Cartosense, Healthy Networks, Remidio, Sporogenics, and X-Zell were selected for the Medtech Innovator Asia Pacific competition, now in its second year.
What is the future of med-tech innovation in the wake of COVID-19? That was the question addressed during the Advanced Medical Technology Association’s Virtual Medtech Conference, with members of industry providing some insight. “I think … that this is going to be in many ways a turning point,” changing the way stakeholders look at devices and the evidence supporting them, said Tom O’Brien, of Johnson & Johnson’s (J&J) Ethicon unit.
The aging portfolios of drug companies and the emergence of China as it moves to develop more innovative therapies are two signposts from an industry in flux, according to the newly released 2020 Centre for Medicines Research (CMR) International Pharmaceutical R&D Factbook.
The aging portfolios of drug companies and the emergence of China as it moves to develop more innovative therapies are two signposts from an industry in flux, according to the newly released 2020 Centre for Medicines Research (CMR) International Pharmaceutical R&D Factbook.
DUBLIN – Meda AB’s acquisition in 2014 of the veteran Italian specialty pharma firm Rottapharm generated a €1.975 billion (US$2.2 billion) payday for the latter firm’s owners, the Rovati family. A small fraction of that amount is now being recycled into a new investment initiative, Aurora Science, which is a three-way partnership among Monza-based Rottapharm Biotech Srl (the R&D arm of the company that was not part of the Meda transaction), the Milan-based specialty pharma Italfarmaco SpA and Aurora-TT Srl, a Milan-based commercial technology transfer company.
DUBLIN – Meda AB’s acquisition in 2014 of the veteran Italian specialty pharma firm Rottapharm generated a €1.975 billion (US$2.2 billion) payday for the latter firm’s owners, the Rovati family. A small fraction of that amount is now being recycled into a new investment initiative, Aurora Science, which is a three-way partnership among Monza-based Rottapharm Biotech Srl (the R&D arm of the company that was not part of the Meda transaction), the Milan-based specialty pharma Italfarmaco SpA and Aurora-TT Srl, a Milan-based commercial technology transfer company.
BOSTON – The shift to value-based care models and rise in digital technologies is causing medical device companies to rethink how and where they invest in innovation. There's less emphasis on core and adjacent product investments and more focus on transformational advances that don't just add new bells and whistles but expand access, improve outcomes and lower costs. Just what that looks like and how companies are adapting to this new innovation landscape was the focus of a session at the Medtech Conference this week.
TAIPEI, Taiwan – The three-day 2019 BIO Asia-Taiwan Conference and Exhibition opened on Wednesday to discuss how biotechnology could be the next growth engine for Asia. While figures are suggesting Asia is rising as a biotech powerhouse, the region needs to think beyond just capital, talent and patient pool, speakers said.
